M. Andres, A. Feller, V. Arndt, . Nicer-working, and . Group, Trends of incidence, mortality, and survival of multiple myeloma in Switzerland between 1994 and 2013, Cancer Epidemiol, vol.53, pp.105-115, 2018.

P. L. Bergsagel, Where we were, where we are, where we are going: progress in multiple myeloma, Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Meet, pp.199-203, 2014.

S. Thorsteinsdottir, P. W. Dickman, O. Landgren, C. Blimark, M. Hultcrantz et al., Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study, Haematologica, 2018.

A. J. Cowan, C. Allen, A. Barac, H. Basaleem, I. Bensenor et al., Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study, JAMA Oncol, 2016.

T. Facon, J. Y. Mary, C. Hulin, L. Benboubker, M. Attal et al., Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial, Lancet Lond Engl, vol.370, issue.9594, pp.1209-1227, 2007.

C. Hulin, T. Facon, P. Rodon, B. Pegourie, L. Benboubker et al., Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial, J Clin Oncol Off J Am Soc Clin Oncol, vol.27, issue.22, pp.3664-70, 2009.

M. A. Dimopoulos, C. Chen, A. Spencer, R. Niesvizky, M. Attal et al.,

, Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials

J. A. Child, G. J. Morgan, F. E. Davies, R. G. Owen, S. E. Bell et al., High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma, N Engl J Med, vol.348, issue.19, pp.1875-83, 2003.

P. Moreau, T. Facon, M. Attal, C. Hulin, M. Michallet et al., Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial, Blood, vol.99, issue.3, pp.731-736, 2002.

B. Barlogie, R. Hall, A. Zander, K. Dicke, and R. Alexanian, High-dose melphalan with autologous bone marrow transplantation for multiple myeloma, Blood, 1986.

T. J. Mcelwain, M. E. Gore, M. Meldrum, C. Viner, I. R. Judson et al., VAMP followed by high dose melphalan and autologous bone marrow transplantation for multiple myeloma, Bone Marrow Transplant, vol.4, issue.4, pp.109-121, 1989.

M. Attal, V. Lauwers-cances, C. Hulin, X. Leleu, D. Caillot et al.,

B. Lenalidomide, Dexamethasone with Transplantation for Myeloma, N Engl J Med, vol.376, issue.14, pp.1311-1331, 201706.

S. Koeppen, Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy, Oncol Res Treat, vol.37, issue.9, pp.506-519, 2014.

P. M. Aguiar, T. De-mendonça-lima, G. Colleoni, and S. Storpirtis, Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses, Crit Rev Oncol Hematol, vol.113, pp.195-212, 2017.

J. Luo, J. J. Gagne, J. Landon, J. Avorn, and A. S. Kesselheim, Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study, Eur J Cancer Oxf Engl, vol.70, pp.22-33, 1990.

B. Durie, J. Harousseau, J. S. Miguel, J. Bladé, B. Barlogie et al., transplant eligible patients with multiple myeloma: a meta-analysis, Br J Haematol, vol.166, issue.5, pp.702-712, 2014.

P. Moreau, H. Avet-loiseau, T. Facon, M. Attal, M. Tiab et al., Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma, Blood, vol.118, issue.22, pp.5752-5758, 2011.

L. Garderet, S. Iacobelli, P. Moreau, M. Dib, I. Lafon et al., Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the

, Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation, J Clin Oncol Off J Am Soc Clin Oncol, vol.30, issue.20, pp.2475-82, 2012.

S. Wu, C. Zheng, S. Chen, X. Cai, Y. Shi et al., Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients, BioMed Res Int, p.927105, 2015.

L. Rosiñol, A. Oriol, A. I. Teruel, D. Hernández, J. López-jiménez et al., Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma

. Pethema/gem and . Study, Blood, vol.120, issue.8, pp.1589-96, 2012.

L. R. Dachs, B. Hebraud, A. Oriol, A. Colin, R. Rios et al., Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma, Blood, vol.132, issue.1, p.3245, 2018.

B. Paiva, M. Vidriales, J. Cerveró, G. Mateo, J. J. Pérez et al., Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation, Blood, vol.112, issue.10, pp.4017-4040, 2008.

A. C. Rawstron, J. A. Child, R. M. De-tute, F. E. Davies, W. M. Gregory et al., Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study, J Clin Oncol Off J Am Soc Clin Oncol, vol.31, issue.20, pp.2540-2547, 2013.

J. Martinez-lopez, J. J. Lahuerta, F. Pepin, M. González, S. Barrio et al., Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma, Blood, vol.123, issue.20, pp.3073-3082, 2014.

R. Plasmati, F. Pastorelli, M. Cavo, E. Petracci, E. Zamagni et al., Neuropathy in multiple myeloma treated with thalidomide: a prospective study, Neurology, vol.69, issue.6, pp.573-81, 2007.